Loading lessons…
Peptide learning paths
Learn peptides step by step
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
198lessons
8paths
0day streak
0%explored
Start your first lesson
Choose a learning path below or search the library. Progress saves in your browser.
Learning paths
Pick a track — progress rings update as you complete lessons.
9 lessons
8mResearchAdvanced
Peptide Clinical Evidence in 2026: How to Separate Signal from Hype
Peptide research is moving fast. Here is how to read the evidence before turning a headline, mechanism, or social post into a protocol.
8mResearchAdvanced
Peptide Therapy for Sports Injuries: What 2026 Evidence Really Shows
A new sports medicine review puts injury-recovery peptides in context. Some mechanisms are promising, but human evidence, safety data, and regulatory status still matter.
8mPolicyAdvanced
FDA Removes 12 Peptides from Category 2 Restrictions: What Changed in April 2026
The FDA's April 2026 announcement removed 12 peptides from Category 2 restrictions — the biggest regulatory shift in years. BPC-157, TB-500, MOTS-C, GHK-Cu, and Semax are among those affected. Here's what it actually means for your access.
9mResearchAdvanced
RFK Jr., the FDA, and BPC-157: What the 2026 Regulatory Reversal Means for Peptide Access
After years of FDA crackdowns on research peptides, a significant regulatory reversal in 2026 has changed the landscape for BPC-157, TB-500, and MOTS-C. Here's what actually happened and what it means for you.
7mPeptidesIntermediate
FDA Removes GHK-Cu from Category 2: What Peptide Users Need to Know
On April 15, 2026, the FDA announced it will remove injectable GHK-Cu from Category 2 — the list that blocked compounding pharmacies from producing it. This is a major regulatory shift for one of the most studied copper peptides in longevity research.
9mPolicyAdvanced
FDA Reclassifies 12 Peptides: What April 2026's Policy Shift Means for Biohackers
The FDA's April 15, 2026 reclassification of 12 research peptides marks the most significant regulatory shift in the space since the 2023 compounding crackdown. Here's a breakdown of the affected compounds, the new compliance landscape, and how to think about your protocol going forward.
9mPolicyAdvanced
BPC-157 and the 2026 Regulatory Shift: What the HHS Category 1 Push Means for Peptide Access
After years of regulatory limbo, BPC-157 is at the center of a major policy battle. The RFK Jr.-led HHS push to reclassify it as Category 1 could restore legal compounding access—or the FDA could dig in. Here's where things stand.
9mPolicyAdvanced
FDA's Regulatory Shift on Compounded Peptides: What the 2026 Policy Signals Mean for You
A potential FDA regulatory shift on 14 compounded peptides — including BPC-157 and TB-500 — could reshape who gets access to peptide therapy and how. Here's what the current signals actually mean.
10mPolicyAdvanced
FDA Peptide Reclassification 2026: BPC-157, GHK-Cu, and MOTS-C Return to Legal Compounding
After years of regulatory uncertainty, BPC-157, GHK-Cu, and MOTS-C are returning to legal compounding access in 2026. Here's what the FDA reclassification means for peptide researchers.
Also available at /blog for legacy links.